Browsing by Author "Ayman, Fairouz"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Effect of a certain inhibitor of SGLT on thioacetamide-induced liver injury in rats
    (October university for modern sciences and arts, 2022) Ayman, Fairouz; Ayman, Nadeen; Shaban, Nooran; Sherif Salem, Rana
    We must first and foremost express our gratitude to Allah, for without his immense mercy and grace, we would not have been able to complete this thesis. In order to continue and complete this thesis, we would like to show our heartfelt gratitude and respect to Dr. Marawan Abdelbaset, Researcher of Pharmacology, Department of Pharmacology, Medical Research, and Clinical Studies Institute, National Research Centre. We value his wise counsel, helpful criticism, and unwavering support. He has been a patient teacher, and we have benefited greatly from him. We won't ever forget the benefits, merits, virtues, and morals he bestowed upon us. He actually serves as a superb illustration of a doctor who excels in both their scientific and moral practices. We owe a great deal of gratitude to Mahmoud Ahmed, a teaching assistant in the pharmacy school's department of pharmacology, for his meticulous oversight and astute direction throughout the project. We would like to thank him for his considerable research experience and the effort he devoted to editing this thesis. It has been an honor to collaborate with him. We are very appreciative of Dr. Dina Sabry for her invaluable assistance and for conducting the investigations. We sincerely want to thank our parents for supporting our desire to pursue higher education. We must never forget to express our gratitude to the friends and coworkers we have had the pleasure of working with. They definitely helped, during the course of this thesis' years, encouraged and offered us advice.
  • Thumbnail Image
    Item
    Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis
    (Multidisciplinary Digital Publishing Institute (MDPI), 2022-10) ElBaset, Marwan A; Salem, Rana S; Ayman, Fairouz; Ayman, Nadeen; Shaban, Nooran; Afifi, Sherif M; Esatbeyoglu, Tuba; Abdelaziz, Mahmoud; Elalfy, Zahraa S
    Hepatic fibrosis causes severe morbidity and death. No viable treatment can repair fibrosis and protect the liver until now. We intended to discover the empagliflozin’s (EMPA) hepatoprotective efficacy in thioacetamide (TAA)-induced hepatotoxicity by targeting AMPK/SIRT-1 activity and reducing HIF-1α. Rats were treated orally with EMPA (3 or 6 mg/kg) with TAA (100 mg/kg, IP) thrice weekly for 6 weeks. EMPA in both doses retracted the serum GGT, ALT, AST, ammonia, triglycerides, total cholesterol, and increased serum albumin. At the same time, EMPA (3 or 6 mg/kg) replenished the hepatic content of GSH, ATP, AMP, AMPK, or SIRT-1 and mitigated the hepatic content of MDA, TNF-α, IL-6, NF-κB, or HIF-1α in a dose-dependent manner. Likewise, hepatic photomicrograph stained with hematoxylin and eosin or Masson trichrome stain of EMPA (3 or 6 mg/kg) revealed marked regression of the hepatotoxic effect of TAA with minimal injury. Similarly, in rats given EMPA (3 or 6 mg/kg), the immunohistochemically of hepatic photomicrograph revealed minimal stain of either α-SMA or caspase-3 compared to the TAA group. Therefore, we concluded that EMPA possessed an antifibrotic effect by targeting AMPK/SIRT-1 activity and inhibiting HIF-1α. The present study provided new insight into a novel treatment of liver fibrosis.